EyePoint Pharma falls on pricing $150 mln stock offering
** Shares of EyePoint Pharmaceuticals 
EYPT down 6.9% premarket at $12.25 after overnight $150 mln follow-on priced
** Co late Tues sold 12.5 mln shares, including 1.5 mln pre-funded warrants, at $12, an 8.8% discount to last sale
** It intends to use net offering proceeds to advance development of its drug, Duravyu, for wet age related macular degeneration (wet AMD) and diabetic macular edema (DME), and support earlier stage pipeline development initiatives
** After the bell Tues, co announced Phase 3 program initiation for Duravyu in DME, an eye condition that causes blurry vision in people with diabetes, with first patient dosing anticipated in Q1 2026
** JP Morgan, Jefferies, Citigroup, and Guggenheim Secs are joint bookrunners for stock offering
** Watertown, Massachusetts-based EYPT has ~69 mln shares outstanding for $907 mln market cap through Tues
** Through Tues close, shares had gained about 77% YTD
** All 13 analysts covering the stock are bullish, including 4 "strong buy" ratings; median PT is $29.50, per LSEG data
